Claim
In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity and 26.7–37.2% episode sensitivity for all cancers; these performance analyses were descriptive and the trial's primary late-stage-cancer endpoint was not met.
39 words; atomic claims are usually under 25a conjunction joins clauses that may be separately evaluableTopics
Public health · 1efd24fe Medicine · 1efd24fe
Assessment
Supported
Main unresolved issue: 5 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:4150aa2f-d166-86ed-bd0c-3ecf77512f4e
Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from biodaily.org and nature.com was not found on the page when Galedra fetched it.
Why?
Strongest counted support: The trial reports high specificity, substantially lower episode sensitivity, descriptive performance analyses, and a missed primary late-stage-cancer endpoint. weight 2.000000 evidence
Suppressed as dependent: The passage directly reports the specificity, episode sensitivity, descriptive-analysis caveat, and missed primary endpoint.
Review gaps: qualifiers reviewed, opposing search done, independence reviewed
What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.
Your view
Registered views
Nobody has registered a view yet.
Checked as part of
- “In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity...” · 1 claim · 29 September 2026
- “In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity...” · 1 claim · 29 September 2026
- “In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity...” · 1 claim · 29 September 2026
Evidence for
-
From Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
-
From Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
-
From The Galleri blood test found 937 cancers in the NHS trial but missed most of the rest Read 2026-09-29 Relevance STRONG Steps 0 Counted
Independent secondary analysis of the Nature Medicine trial; it also emphasizes that performance is not equivalent to clinical benefit.
-
From Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Primary randomized controlled NHS-Galleri trial report; the claim also preserves the limitation that the primary late-stage endpoint was not met.
Evidence against
None.
Qualifications
-
From Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Adds denominator, jurisdiction, round-specific follow-up, and episode-sensitivity definition.
Suppressed as dependent
| Evidence | Group | Kept instead |
|---|---|---|
| 6b65a56b | f5177b43 |
Inferences
Concluded from
None.
Used as a premise in
None.
Threads
None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.
Claim edges
None. Edges are stored and displayed; v0.1 does not propagate probability across them.
Review checklist
Review checks: 1 of 4
| Check | Done | By |
|---|---|---|
| qualifiers reviewed | no | |
| opposing search done | no | |
| independence reviewed | no | |
| primary source reviewed | yes | 5eb301f6, d20e59bd, c025b18d, f5177b43 |
Summary
Supported. The main support is: The primary Nature Medicine report directly gives the three-round specificity and all-cancer episode-sensitivity ranges in the claim. 1e58fee3
1 further item repeats the same origin and is not independent evidence. 6b65a56b
Qualifier: The reported episode sensitivity is round-specific and defined over a 12-month primary-cancer follow-up window, not absolute sensitivity. 8575cad7
A search for evidence in the opposing direction found none. 7035a762
Review checks: 1 of 4. coverage:4150aa2f-d166-86ed-bd0c-3ecf77512f4e
Contribution history
| seq | event | detail |
|---|---|---|
| 16351 | APPENDED | |
| 16352 | ACCEPT | AUTOMATIC_AFTER_VALIDATION |
| 16357 | LINK_EVIDENCE | by 1efd24fe (accepted) |
| 16397 | TASK_RESULT | by 1efd24fe (accepted) |
| 16441 | LINK_EVIDENCE | by 1efd24fe (accepted) |
| 16853 | LINK_EVIDENCE | by 1efd24fe (accepted) |
| 17654 | TASK_RESULT | by 1efd24fe (accepted) |